Takeda Faces $2.46 Billion Jury Verdict in AMITIZA Antitrust Case; Plans Appeal

summarizeSummary

Takeda was hit with a nearly $2.5 billion potential liability from a U.S. antitrust jury verdict related to its AMITIZA drug, which the company plans to appeal.

check_boxKey Events

• Jury Verdict Against Takeda

  A U.S. jury found Takeda liable in the AMITIZA antitrust litigation, awarding plaintiffs $884.9 million in single damages.

• Potential Trebled Damages

  Approximately $2.46 billion of the awarded damages (for wholesaler and retailer classes) will be automatically trebled under U.S. antitrust law. Damages for the end payor class are subject to further proceedings.

• Company Plans Appeal

  Takeda stated it will vigorously pursue post-trial motions and an appeal, believing the case lacks merit and citing evidentiary and legal errors.

• Financial Statement Revision

  Takeda will recognize a provision in its FY2025 consolidated financial statements, requiring a revision and re-filing of its FY2025 earnings report.

auto_awesomeAnalysis

A U.S. jury found Takeda liable in an antitrust lawsuit related to its AMITIZA drug, awarding plaintiffs $884.9 million in single damages. A significant portion of these damages, totaling approximately $2.46 billion, will be automatically trebled under U.S. antitrust law. While Takeda plans to vigorously appeal the verdict and states no impact on core financial results, the company will need to recognize a substantial provision in its FY2025 financial statements, leading to a revision of its earnings report and potentially impacting adjusted free cash flow. This represents a major legal and financial setback.